Kancera AB – Product Pipeline Review

Global Markets Direct’s, ‘Kancera AB – Product Pipeline Review – 2016’, provides an overview of the Kancera AB’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kancera AB, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Kancera AB

The report provides overview of Kancera AB including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Kancera AB’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Kancera AB’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Kancera AB’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Kancera AB

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Kancera AB’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Kancera AB Snapshot 5

Kancera AB Overview 5

Key Information 5

Key Facts 5

Kancera AB - Research and Development Overview 6

Key Therapeutic Areas 6

Kancera AB - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

Kancera AB - Pipeline Products Glance 13

Kancera AB - Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Discovery Products/Combination Treatment Modalities 14

Kancera AB - Drug Profiles 15

KAN-0437757 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

KAN-0438757 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

KAN-0439834 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Monoclonal Antibodies to Target ROR-1 for Chronic Lymphocytic Leukemia and Melanoma 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

KAN-0439221 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

KAN-043936 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

KAN-0439363 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

KAN-0439365 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

KAN-0439828 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

KAN-0439829 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

KAN-439782 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecule for Malaria 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecule for Schistosomiasis 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Small Molecules to Inhibit HDAC6 for Oncology 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Kancera AB - Pipeline Analysis 31

Kancera AB - Pipeline Products by Target 31

Kancera AB - Pipeline Products by Route of Administration 32

Kancera AB - Pipeline Products by Molecule Type 33

Kancera AB - Pipeline Products by Mechanism of Action 34

Kancera AB - Recent Pipeline Updates 35

Kancera AB - Dormant Projects 36

Kancera AB - Discontinued Pipeline Products 37

Discontinued Pipeline Product Profiles 37

Small Molecules To Agonize GPR-119 For Type 2 Diabetes 37

Small Molecules To Inhibit SCD1 For Obesity And Diabetes 37

Kancera AB - Locations And Subsidiaries 38

Head Office 38

Appendix 39

Methodology 39

Coverage 39

Secondary Research 39

Primary Research 39

Expert Panel Validation 39

Contact Us 39

Disclaimer 40

List of Tables

List of Tables

Kancera AB, Key Information 5

Kancera AB, Key Facts 5

Kancera AB – Pipeline by Indication, 2016 7

Kancera AB – Pipeline by Stage of Development, 2016 9

Kancera AB – Monotherapy Products in Pipeline, 2016 10

Kancera AB – Partnered Products in Pipeline, 2016 11

Kancera AB – Partnered Products/ Combination Treatment Modalities, 2016 12

Kancera AB – Preclinical, 2016 13

Kancera AB – Discovery, 2016 14

Kancera AB – Pipeline by Target, 2016 31

Kancera AB – Pipeline by Route of Administration, 2016 32

Kancera AB – Pipeline by Molecule Type, 2016 33

Kancera AB – Pipeline Products by Mechanism of Action, 2016 34

Kancera AB – Recent Pipeline Updates, 2016 35

Kancera AB – Dormant Developmental Projects,2016 36

Kancera AB – Discontinued Pipeline Products, 2016 37

List of Figures

List of Figures

Kancera AB – Pipeline by Top 10 Indication, 2016 7

Kancera AB – Pipeline by Stage of Development, 2016 9

Kancera AB – Monotherapy Products in Pipeline, 2016 10

Kancera AB – Pipeline by Target, 2016 31

Kancera AB – Pipeline by Molecule Type, 2016 33

Kancera AB – Pipeline Products by Mechanism of Action, 2016 34

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports